Search results
Showing 1381 to 1395 of 8314 results
NICE is unable to make a recommendation on treosulfan (Trecondi) with fludarabine before allogeneic stem cell transplant for babies, children and young people aged 1 month to 17 years with non-malignant diseases. This is because Medac Pharma did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA945
Tofacitinib for treating juvenile idiopathic arthritis (TA735)
Evidence-based recommendations on tofacitinib for treating juvenile idiopathic arthritis.
Evidence-based recommendations on capivasertib (Truqap) with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment in adults.
Evidence-based recommendations on lenalidomide (Revlimid) for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality in adults.
View recommendations for TA322Show all sections
Prucalopride for the treatment of chronic constipation in women (TA211)
Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women.
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)
Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin for people with mild chronic hepatitis C.
Evidence-based recommendations on laparoscopic surgery for people with colorectal cancer.
Gemcitabine for the treatment of metastatic breast cancer (TA116)
Evidence-based recommendations on gemcitabine for treating metastatic breast cancer in adults.
Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism in people with end-stage renal disease who are on dialysis.
Methadone and buprenorphine for the management of opioid dependence (TA114)
Evidence-based recommendations on methadone and buprenorphine (oral formulations) for managing opioid dependence in adults.
Evidence-based recommendations on naltrexone (Nalorex) for managing opioid dependence in adults.
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer in adults.
Ozanimod for treating moderately to severely active ulcerative colitis (TA828)
Evidence-based recommendations on ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatments cannot be tolerated or are not working well enough.
After discussion with Paion AG, NICE is unable to make a recommendation on angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock. The company did not make an evidence submission because of uncertainty about the number of people who would be eligible for treatment. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA859
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
Evidence-based recommendations on botulinum toxin type A (Botox) for preventing headaches in adults with chronic migraine.